News
August 30, 2023
New Investigational Therapy for Lupus Treatment, GLPG3667, Begins Phase 2 Study
A new investigational therapy, GLPG3667, for adults with active lupus is beginningPhase 2 study to examine the safety, tolerability and efficacy of the treatment. The therapy is a tyrosine kinase 2 or TYK2 enzyme inhibitor, which prevents inflammation. TYK2 is a critical driver of disease in lupus.
The GALACELA trial will enroll approximately 140 adults with lupus who will receive the treatment orally once per day or placebo for 32 weeks.
Continue to follow the Lupus Foundation of America for updates on GLPG3667 as well as other lupus clinical trials.
See More:
The latest from Inside Lupus Research
Experimental Treatment, Zetomipzomib, for Lupus Nephritis to be Developed and Marketed in Asia
News
Predictors for the Development of Systemic Lupus Erythematosus in People with Sjogren’s Syndrome
News
New Study Examines the Benefits of Ginger Supplements in Autoimmune Diseases Like Lupus
News
$3 Million Grant Awarded to Develop Artificial Intelligence to Help Diagnose Lupus Nephritis
News